Yun Wang

  • Senior consultant; MD, PhD
  • +47 22 93 44 54

Dr. Wang got her Medical Degree from Dalian Medical University in China. She completed her residency training in the Department of Gynecology and Obstetrics at the Second Affiliated Hospital of Dalian Medical University in China in 1995. Subsequently, she served as a gynecologist at the same institution until she was awarded a scholarship by the Norwegian Research Council in 1999.

She successfully obtained her PhD from the Faculty of Medicine at Oslo University in Norway in 2005, followed by receiving Norwegian authorization as a medical doctor in March 2007. Her professional journey led her to the Department of Gynecology and Obstetrics at Oslo University Hospital - The National Hospital, where she worked from 2007 to 2010. Since then, Dr. Wang has been dedicatedly contributing her expertise to the Department of Gynecologic Oncology at Oslo University Hospital - the Norwegian Radium Hospital. She delivers both surgical and medical treatments for women afflicted by gynecologic malignancies. 

Dr. Wang leads the Ovarian Cancer Surgical Treatment Team and the Vulvar Cancer Team at Oslo University Hospital - the Norwegian Radium Hospital. Her primary clinical focus revolves around cytoreductive operations for advanced ovarian cancer, advanced minimally invasive surgery for gynecologic cancer, and advanced procedures involving vulvar reconstruction for vulvar cancer.

Publications in chinese

Wang Y, Chang D-An.   Histochemical study of carbohydrate of human endosalphinx.  Reproduction and Contraception, 1994; 14(2): 101 - 107  (In Chinese)

Wang Y, Tang HJ.   Clinical analysis of 66 cases of persistent occiput posterior position. Journal of Postgraduates of Medicine 1998; 21: 82 -83  (In Chinese)

Wang Y,  Meng YQ,  Wu BT, Zhao CHY.  The study of IL-8 concentrations in peritoneal fluid of women with endometriosis.  Chinese Journal of Obstetrics and Gynecology 1998; 33(10): 630 - 635  (In Chinese)

Wang Y,  Tang HJ,  Wu BT,  Gao WT,  Zhang X,  Gao XSH.  Laboratorial study of Chinese herb "CuShengTang" on promoting the cervical ripening of the pregnant mice.  Chinese  Journal of  traditional  medical science and technology,1999; 2: 75 - 80  (In Chinese)

Book In Chinese

Editor:  Wang X, Ya Zh, Wang Y  Compulsory reader of Climacteric  Syndrome. Shen Yang Publishing Company, 1998.

 

Publications 2023

Davidson B, Skeie-Jensen T, Holth A, Lindemann K, Toralba Barrameda AM, Lie AK, Wang Y (2023)
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
Virchows Arch, 484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640

Valstad H, Eyjolfsdottir B, Wang Y, Kristensen GB, Skeie-Jensen T, Lindemann K (2023)
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis
Eur J Surg Oncol, 49 (9), 106958
DOI 10.1016/j.ejso.2023.06.010, PubMed 37349160

Publications 2021

Eriksson AGZ, Davidson B, Bjerre Trent P, Eyjólfsdóttir B, Dahl GF, Wang Y, Staff AC (2021)
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
J Clin Med, 10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260

Publications 2020

Sharma A, Davidson B, Skeie-Jensen T, Wang Y (2020)
Fifteen Years’ Experience with Vulvar Verrucous Carcinoma at a Single Norwegian Academic Cancer Center
Journal of Gynecology and Women Healthcare, 2 (2), 1-4
PublikaID 489

Zubor P, Wang Y, Liskova A, Samec M, Koklesova L, Dankova Z, Dørum A, Kajo K, Dvorska D, Lucansky V, Malicherova B, Kasubova I, Bujnak J, Mlyncek M, Dussan CA, Kubatka P, Büsselberg D, Golubnitschaja O (2020)
Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
Int J Mol Sci, 21 (21)
DOI 10.3390/ijms21217988, PubMed 33121141

Publications 2018

Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455

Publications 2014

Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937
DOI 10.1186/1471-2407-14-937, PubMed 25494701

Publications 2013

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714

Publications 2011

Wang Y, Brinch L, Jebsen P, Tanbo T, Kirschner R (2011)
A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation
Biol Blood Marrow Transplant, 18 (5), 747-53
DOI 10.1016/j.bbmt.2011.09.012, PubMed 21963879

Wang Y, Tanbo T, Ellingsen L, Abyholm T, Henriksen T (2011)
Effect of pregestational maternal, obstetric and perinatal factors on neonatal outcome in extreme prematurity
Arch Gynecol Obstet, 284 (6), 1381-7
DOI 10.1007/s00404-011-1870-5, PubMed 21387086

Publications 2010

Wang Y, Tanbo T, Abyholm T, Henriksen T (2010)
The impact of advanced maternal age and parity on obstetric and perinatal outcomes in singleton gestations
Arch Gynecol Obstet, 284 (1), 31-7
DOI 10.1007/s00404-010-1587-x, PubMed 20632182

Publications 2009

Kamalakaran S, Kendall J, Zhao X, Tang C, Khan S, Ravi K, Auletta T, Riggs M, Wang Y, Helland A, Naume B, Dimitrova N, Børresen-Dale AL, Hicks J, Lucito R (2009)
Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation
Nucleic Acids Res, 37 (12), e89
DOI 10.1093/nar/gkp413, PubMed 19474344

Publications 2007

Wang Y, Kristensen GB, Børresen-Dale AL, Helland A (2007)
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
Ann Oncol, 18 (5), 964-6
DOI 10.1093/annonc/mdm134, PubMed 17488735

Publications 2006

Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006)
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
DOI 10.1371/journal.pmed.0030047, PubMed 16417408

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MMO, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2006)
Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
Hum. Mutat., 27 (2), 209-210
DOI 10.1002/humu.20298

Publications 2005

Benetkiewicz M, Wang Y, Schaner M, Wang P, Mantripragada KK, Buckley PG, Kristensen G, Børresen-Dale AL, Dumanski JP (2005)
High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
Genes Chromosomes Cancer, 42 (3), 228-37
DOI 10.1002/gcc.20128, PubMed 15578687

Kringen P, Bergamaschi A, Due EU, Wang Y, Tagliabue E, Nesland JM, Nehman A, Tönisson N, Børresen-Dale AL (2005)
Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas
Biotechniques, 39 (5), 755-61
DOI 10.2144/000112000, PubMed 16312222

Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A (2005)
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507

Publications 2004

Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786

Publications 2001

Wang Y, Fedorcsák P, Dale PO, Storeng R, Abyholm T, Tanbo T (2001)
Simplification of continuous infusion of glucose with model assessment in the evaluation of insulin resistance in women with PCOS
Gynecol Endocrinol, 15 (3), 192-7
PubMed 11447730

Wang Y, Storeng R, Dale PO, Abyholm T, Tanbo T (2001)
Effects of follicular fluid and steroid hormones on chemotaxis and motility of human spermatozoa in vitro
Gynecol Endocrinol, 15 (4), 286-92
DOI 10.1080/gye.15.4.286.292, PubMed 11560102

Page visits: 23411